Breaking News Instant updates and real-time market news.

AMGN

Amgen

$166.71

-2.37 (-1.40%)

09:03
06/03/19
06/03
09:03
06/03/19
09:03

Amgen: 5 patients experienced partial response in AMG 510 Phase 1 study

Amgen announced the first clinical results from a Phase 1 study evaluating investigational AMG 510, the first KRASG12C inhibitor to reach the clinical stage. In the trial, there were no dose-limiting toxicities at tested dose levels. AMG 510 showed anti-tumor activity when administered as a monotherapy in patients with locally-advanced or metastatic KRASG12C mutant solid tumors. These data are being presented during an oral session at the 55th Annual Meeting of the American Society of Clinical Oncology in Chicago. The Phase 1, first-in-human, open-label multicenter study enrolled 35 patients with various tumor types. Eligible patients were heavily pretreated with at least two or more prior lines of treatment, consistent with their tumor type and stage of disease. The primary endpoint is safety, and key secondary endpoints include pharmacokinetics, objective response rate, duration of response and progression-free survival. Patients were enrolled in four dose cohorts - 180 mg, 360 mg, 720 mg and 960 mg, taken orally once a day. Five out of 10 evaluable patients with NSCLC experienced a partial response, and another four had stable disease, for a disease control rate of 90 percent. All five patients with response to therapy had a treatment duration of 7.3-27.4 weeks at data cutoff and remain active on treatment. One patient with PR improved further to a complete response of the target lesions at week 18, post data cutoff. In addition, 13 of 18 evaluable patients with CRC achieved SD, with the majority of CRC patients treated at the first two dose levels. Twenty-six patients remain on study and nine have discontinued. "KRAS has been a target of active exploration in cancer research since it was identified as one of the first oncogenes more than 30 years ago, but it remained undruggable due to a lack of traditional small molecule binding pockets on the protein. AMG 510 seeks to crack the KRAS code by exploiting a previously hidden groove on the protein surface," said David M. Reese, M.D., executive vice president of Research and Development at Amgen. "By irreversibly binding to cysteine 12 on the mutated KRAS protein, AMG 510 is designed to lock it into an inactive state. With high selectivity for KRASG12C, we believe investigational AMG 510 has high potential as both a monotherapy and in combination with other targeted and immune therapies."

  • 03

    Jun

AMGN Amgen
$166.71

-2.37 (-1.40%)

05/20/19
FBCO
05/20/19
INITIATION
Target $208
FBCO
Outperform
Amgen initiated with an Outperform at Credit Suisse
Credit Suisse analyst Evan Seigerman initiated Amgen with an Outperform rating and a price target of $208, saying the stock is "attractive" relative to its peers because of its "underappreciated" biosimilars assets that may offset the expected revenue decline in its core business. The analyst is also positive on Amgen's promising pipeline that includes oncology and immunology assets along with its discounted valuation, noting that the stock is currently trading at 12.1-times expected forward earnings vs. 17.7-times for the S&P500 and 14.4-times or more for its major pharma peers.
05/22/19
SBSH
05/22/19
UPGRADE
SBSH
Buy
Amgen upgraded to Buy from Neutral at Citi
05/22/19
05/22/19
UPGRADE

Citi assumes coverage of large-cap biotech, upgrades Amgen and Gilead
Citi analyst Mohit Bansal assumed coverage of large-cap biotech stocks, assuming coverage with five Buy ratings -- Amgen (AMGN), Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), and BioMarin Pharmaceutical (BMRN) -- and two Neutral ratings -- Biogen (BIIB) and Regeneron Pharmaceuticals (REGN). Both Amgen and Gilead were upgraded to Buy from Neutral as part of the assumption of coverage. The analyst said he is "more optimistic" on the sector as a whole as he sees many biotechs going "back to basics" by investing in their internal pipelines and filling their pipelines with early stage assets. He suggests looking at large caps again, as many are returning to stability and growth. Bansal does not favor large M&A, suggesting discipline due to "realizing value with big M&As."
05/24/19
OPCO
05/24/19
NO CHANGE
Target $210
OPCO
Outperform
Amgen management comments 'encouraging,' says Oppenheimer
Oppenheimer analyst Jay Olson maintained an Outperform rating and $210 price target on Amgen after meeting with the company, saying he maintains his bullish stance. In a research note to investors, Olson says he is "encouraged" by Amgen's comments on the current status of Enbrel, Repatha potential with the lower list price, Aimovig launch and CGRP market dynamics, the oncology pipeline and capital allocation.

TODAY'S FREE FLY STORIES

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

POAI

Predictive Oncology

$0.44

0.0101 (2.35%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Conference/Events
Predictive Oncology to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

BK

BNY Mellon

$45.34

0.975 (2.20%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
BNY Mellon SVP Harris sells 50K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:40
10/18/19
10/18
16:40
10/18/19
16:40
Hot Stocks
Breaking Hot Stocks news story on Foamix 

Foamix trading resumes

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

BAC

Bank of America

$30.37

0.1 (0.33%)

16:35
10/18/19
10/18
16:35
10/18/19
16:35
Hot Stocks
Bank of America's Knox sells 40,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

LGC

Legacy Acquisition Corp

$10.24

0.02 (0.20%)

16:34
10/18/19
10/18
16:34
10/18/19
16:34
Conference/Events
Legacy Acquisition Corp to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MFGP

Micro Focus

$15.13

0.56 (3.84%)

, OTEX

OpenText

$39.30

-1.545 (-3.78%)

16:33
10/18/19
10/18
16:33
10/18/19
16:33
Periodicals
OpenText weighing takeover bid for rival Micro Focus, Bloomberg says »

Open Text (OTEX) is…

MFGP

Micro Focus

$15.13

0.56 (3.84%)

OTEX

OpenText

$39.30

-1.545 (-3.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 06

    Nov

  • 19

    Nov

16:30
10/18/19
10/18
16:30
10/18/19
16:30
Options
Preliminary option volume of 21.9M today »

Preliminary option volume…

BA

Boeing

$344.01

-25.12 (-6.81%)

, ORCL

Oracle

$54.55

-0.52 (-0.94%)

16:22
10/18/19
10/18
16:22
10/18/19
16:22
On The Fly
Fly Intel: Wall Street's top stories for Friday »

U.S. earnings have…

BA

Boeing

$344.01

-25.12 (-6.81%)

ORCL

Oracle

$54.55

-0.52 (-0.94%)

KO

Coca-Cola

$54.78

0.98 (1.82%)

AXP

American Express

$116.82

-2.35 (-1.97%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

M

Macy's

$15.11

-0.66 (-4.19%)

LB

L Brands

$16.32

-1.78 (-9.83%)

GPS

Gap

$16.87

-0.71 (-4.04%)

LEVI

Levi Strauss

$17.12

0.07 (0.41%)

DERM

Dermira

$7.17

1.49 (26.23%)

ETFC

E-Trade

$40.82

1.78 (4.56%)

GIL

Gildan Activewear

$26.29

-9.085 (-25.68%)

TEAM

Atlassian

$116.96

-5.47 (-4.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 31

    Oct

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 06

    Dec

  • 07

    Dec

EYEG

EyeGate

$3.40

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
10/18/19
10/18
16:20
10/18/19
16:20
Options
Closing CBOE SPX and VIX Index summary for October 18th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$20.36

0.36 (1.80%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Hot Stocks
Glenview Capital discloses 14.7% activist stake in Meritor »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

BCBP

BCB Bancorp

$12.91

-0.04 (-0.31%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Earnings
BCB Bancorp reports Q3 EPS 30c, consensus 30c »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
10/18/19
10/18
16:17
10/18/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
10/18/19
10/18
16:16
10/18/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTI

Universal Technical

$5.35

0.12 (2.29%)

16:15
10/18/19
10/18
16:15
10/18/19
16:15
Syndicate
Breaking Syndicate news story on Universal Technical »

Universal Technical files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNH

UnitedHealth

$246.37

2.62 (1.07%)

16:13
10/18/19
10/18
16:13
10/18/19
16:13
Hot Stocks
UnitedHealth's Burke sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:09
10/18/19
10/18
16:09
10/18/19
16:09
Hot Stocks
Foamix announces FDA approval of AMZEEQ topical foam, 4% »

Foamix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees Q3 net sales $325M, consensus $348.82M »

Michael F. Barry,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KWR

Quaker Chemical

$160.98

-2.04 (-1.25%)

16:05
10/18/19
10/18
16:05
10/18/19
16:05
Earnings
Quaker Houghton sees FY19 pro forma adjusted EBITDA down 2%-4% »

Quaker Houghton updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$36.28

0.08 (0.22%)

16:04
10/18/19
10/18
16:04
10/18/19
16:04
Periodicals
GM to build new electric pickups, SUVs at Detrioit-Hamtramck plant, Reuters says »

Beginning in late 2021,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

FCCY

1st Constitution Bancorp

$19.04

-0.09 (-0.47%)

, SHRC

Shore Community Bank

$0.00

(0.00%)

16:02
10/18/19
10/18
16:02
10/18/19
16:02
Hot Stocks
Shore shareholders approve of merger with 1st Constitution Bancorp »

1ST Constitution Bancorp…

FCCY

1st Constitution Bancorp

$19.04

-0.09 (-0.47%)

SHRC

Shore Community Bank

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

CHMG

Chemung Financial

$42.84

-0.09 (-0.21%)

16:01
10/18/19
10/18
16:01
10/18/19
16:01
Earnings
Chemung Financial reports Q3 EPS 40c, consensus 29c »

Anders Tomson, Chemung…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

GM

General Motors

$36.30

0.1 (0.28%)

15:55
10/18/19
10/18
15:55
10/18/19
15:55
Periodicals
Breaking Periodicals news story on General Motors »

GM to build new electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.